818 related articles for article (PubMed ID: 25922428)
1. Myeloid-Derived Suppressor Cells as an Immune Parameter in Patients with Concurrent Sunitinib and Stereotactic Body Radiotherapy.
Chen HM; Ma G; Gildener-Leapman N; Eisenstein S; Coakley BA; Ozao J; Mandeli J; Divino C; Schwartz M; Sung M; Ferris R; Kao J; Wang LH; Pan PY; Ko EC; Chen SH
Clin Cancer Res; 2015 Sep; 21(18):4073-4085. PubMed ID: 25922428
[TBL] [Abstract][Full Text] [Related]
2. Sunitinib mediates reversal of myeloid-derived suppressor cell accumulation in renal cell carcinoma patients.
Ko JS; Zea AH; Rini BI; Ireland JL; Elson P; Cohen P; Golshayan A; Rayman PA; Wood L; Garcia J; Dreicer R; Bukowski R; Finke JH
Clin Cancer Res; 2009 Mar; 15(6):2148-57. PubMed ID: 19276286
[TBL] [Abstract][Full Text] [Related]
3. MDSC as a mechanism of tumor escape from sunitinib mediated anti-angiogenic therapy.
Finke J; Ko J; Rini B; Rayman P; Ireland J; Cohen P
Int Immunopharmacol; 2011 Jul; 11(7):856-61. PubMed ID: 21315783
[TBL] [Abstract][Full Text] [Related]
4. [Effect of concurrent chemoradiotherapy and radiotherapy alone on peripheral myeloid-derived suppressor and T regulatory cells in patients with nasopharyngeal cancer].
Dai XC; Liu LQ; Wang BH; Wang CM; Ma L; Cao WM; Dai EX
Zhonghua Zhong Liu Za Zhi; 2017 Aug; 39(8):579-583. PubMed ID: 28835079
[No Abstract] [Full Text] [Related]
5. Myeloid derived suppressor cell infiltration of murine and human gliomas is associated with reduction of tumor infiltrating lymphocytes.
Raychaudhuri B; Rayman P; Huang P; Grabowski M; Hambardzumyan D; Finke JH; Vogelbaum MA
J Neurooncol; 2015 Apr; 122(2):293-301. PubMed ID: 25579983
[TBL] [Abstract][Full Text] [Related]
6. Functional characterization of human Cd33+ and Cd11b+ myeloid-derived suppressor cell subsets induced from peripheral blood mononuclear cells co-cultured with a diverse set of human tumor cell lines.
Lechner MG; Megiel C; Russell SM; Bingham B; Arger N; Woo T; Epstein AL
J Transl Med; 2011 Jun; 9():90. PubMed ID: 21658270
[TBL] [Abstract][Full Text] [Related]
7. Monocytic myeloid-derived suppressor cells accumulate in renal transplant patients and mediate CD4(+) Foxp3(+) Treg expansion.
Luan Y; Mosheir E; Menon MC; Wilson D; Woytovich C; Ochando J; Murphy B
Am J Transplant; 2013 Dec; 13(12):3123-31. PubMed ID: 24103111
[TBL] [Abstract][Full Text] [Related]
8. A circulating subpopulation of monocytic myeloid-derived suppressor cells as an independent prognostic/predictive factor in untreated non-small lung cancer patients.
Vetsika EK; Koinis F; Gioulbasani M; Aggouraki D; Koutoulaki A; Skalidaki E; Mavroudis D; Georgoulias V; Kotsakis A
J Immunol Res; 2014; 2014():659294. PubMed ID: 25436215
[TBL] [Abstract][Full Text] [Related]
9. Population alterations of L-arginase- and inducible nitric oxide synthase-expressed CD11b+/CD14⁻/CD15+/CD33+ myeloid-derived suppressor cells and CD8+ T lymphocytes in patients with advanced-stage non-small cell lung cancer.
Liu CY; Wang YM; Wang CL; Feng PH; Ko HW; Liu YH; Wu YC; Chu Y; Chung FT; Kuo CH; Lee KY; Lin SM; Lin HC; Wang CH; Yu CT; Kuo HP
J Cancer Res Clin Oncol; 2010 Jan; 136(1):35-45. PubMed ID: 19572148
[TBL] [Abstract][Full Text] [Related]
10. Myeloid-derived suppressor cell measurements in fresh and cryopreserved blood samples.
Kotsakis A; Harasymczuk M; Schilling B; Georgoulias V; Argiris A; Whiteside TL
J Immunol Methods; 2012 Jul; 381(1-2):14-22. PubMed ID: 22522114
[TBL] [Abstract][Full Text] [Related]
11. Increased frequencies of CD11b(+) CD33(+) CD14(+) HLA-DR(low) myeloid-derived suppressor cells are an early event in melanoma patients.
Rudolph BM; Loquai C; Gerwe A; Bacher N; Steinbrink K; Grabbe S; Tuettenberg A
Exp Dermatol; 2014 Mar; 23(3):202-4. PubMed ID: 24495013
[TBL] [Abstract][Full Text] [Related]
12. Correlation between frequencies of blood monocytic myeloid-derived suppressor cells, regulatory T cells and negative prognostic markers in patients with castration-resistant metastatic prostate cancer.
Idorn M; Køllgaard T; Kongsted P; Sengeløv L; Thor Straten P
Cancer Immunol Immunother; 2014 Nov; 63(11):1177-87. PubMed ID: 25085000
[TBL] [Abstract][Full Text] [Related]
13. Tumor-induced myeloid-derived suppressor cell subsets exert either inhibitory or stimulatory effects on distinct CD8+ T-cell activation events.
Schouppe E; Mommer C; Movahedi K; Laoui D; Morias Y; Gysemans C; Luyckx A; De Baetselier P; Van Ginderachter JA
Eur J Immunol; 2013 Nov; 43(11):2930-42. PubMed ID: 23878002
[TBL] [Abstract][Full Text] [Related]
14. Direct and differential suppression of myeloid-derived suppressor cell subsets by sunitinib is compartmentally constrained.
Ko JS; Rayman P; Ireland J; Swaidani S; Li G; Bunting KD; Rini B; Finke JH; Cohen PA
Cancer Res; 2010 May; 70(9):3526-36. PubMed ID: 20406969
[TBL] [Abstract][Full Text] [Related]
15. Yeast-Derived Particulate β-Glucan Treatment Subverts the Suppression of Myeloid-Derived Suppressor Cells (MDSC) by Inducing Polymorphonuclear MDSC Apoptosis and Monocytic MDSC Differentiation to APC in Cancer.
Albeituni SH; Ding C; Liu M; Hu X; Luo F; Kloecker G; Bousamra M; Zhang HG; Yan J
J Immunol; 2016 Mar; 196(5):2167-80. PubMed ID: 26810222
[TBL] [Abstract][Full Text] [Related]
16. Immunosuppressive role of CD11b
Hyun SY; Na EJ; Jang JE; Chung H; Kim SJ; Kim JS; Kong JH; Shim KY; Lee JI; Min YH; Cheong JW
Cancer Med; 2020 Oct; 9(19):7007-7017. PubMed ID: 32780544
[TBL] [Abstract][Full Text] [Related]
17. Immunosuppressive effects and mechanisms of three myeloid-derived suppressor cells subsets including monocytic-myeloid-derived suppressor cells, granulocytic-myeloid-derived suppressor cells, and immature-myeloid-derived suppressor cells.
Nagatani Y; Funakoshi Y; Suto H; Imamura Y; Toyoda M; Kiyota N; Yamashita K; Minami H
J Cancer Res Ther; 2021; 17(4):1093-1100. PubMed ID: 34528569
[TBL] [Abstract][Full Text] [Related]
18. Treatment Intensification in HIV-Infected Patients Is Associated With Reduced Frequencies of Regulatory T Cells.
Grützner EM; Hoffmann T; Wolf E; Gersbacher E; Neizert A; Stirner R; Pauli R; Ulmer A; Brust J; Bogner JR; Jaeger H; Draenert R
Front Immunol; 2018; 9():811. PubMed ID: 29760693
[TBL] [Abstract][Full Text] [Related]
19. The novel role of tyrosine kinase inhibitor in the reversal of immune suppression and modulation of tumor microenvironment for immune-based cancer therapies.
Ozao-Choy J; Ma G; Kao J; Wang GX; Meseck M; Sung M; Schwartz M; Divino CM; Pan PY; Chen SH
Cancer Res; 2009 Mar; 69(6):2514-22. PubMed ID: 19276342
[TBL] [Abstract][Full Text] [Related]
20. Clinical Relevance and Suppressive Capacity of Human Myeloid-Derived Suppressor Cell Subsets.
Lang S; Bruderek K; Kaspar C; Höing B; Kanaan O; Dominas N; Hussain T; Droege F; Eyth C; Hadaschik B; Brandau S
Clin Cancer Res; 2018 Oct; 24(19):4834-4844. PubMed ID: 29914893
[No Abstract] [Full Text] [Related]
[Next] [New Search]
